Here's Why You Should Add STERIS (STE) to Portfolio NowHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Here's Why You Should Add STERIS (STE) to Portfolio NowZacks Equity ResearchZacksJanuary 7, 2020ReblogShareTweetShareSTERIS plc STE has been progressing well with its growth strategies of diversifying its product portfolio and pursuing acquisitions.This $12.77-billion worth infection prevention and microbial reduction company’s earnings growth rate is expected to be 9.5% for the next 12 months. Also, the company has a trailing four-quarter positive earnings surprise of 5.5%, on average.In the past year, the company’s shares have outperformed the industry. The stock has rallied 42.1% compared with the industry’s 17.7% growth.Let’s delve deeper into the factors that substantiate the company’s Zacks Rank #2 (Buy).STERIS' Infection Prevention and Sterilization Wing Prospers Globally: With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS has become the new global leader in infection prevention and sterilization. The company is currently providing improved healthcare services to medical device companies, pharma companies, hospitals and other healthcare facilities across the globe. The consolidation, since its inception, has boosted STERIS' presence in the international markets by combining STERIS’ strong presence in North America with Synergy's solid footprint across Europe. The company continues to benefit from the acquisition of Synergy Health. High Potential in Healthcare and Pharmaceutical Industries: The bulk of STERIS’ sales are generated from healthcare and pharmaceutical industries. During the second quarter of fiscal 2020, revenues at the Healthcare Specialty Services segment rose 8% year over year. The segment witnessed improved demand and robust growth on consumables, services and capital equipment. The completion of several tuck-in acquisitions has also strengthened this segment. Given the continued success achieved by the company in offering varied medical equipment to its customers, we believe this segment should continue to drive growth for the company in the long term.Upbeat Guidance: The company has raised its projection for fiscal 2020 adjusted earnings in the range of $5.50-5.65 from the earlier estimate of $5.38-5.53.Constant currency organic revenue growth for fiscal 2020 is expected in the range of 7.5-8.5% compared with the prior projection of 6-7%. This overall bullish trend is likely to continue through the rest of the fiscal 2020.Which Way Are Estimates Treading?For the third quarter of fiscal 2020, the Zacks Consensus Estimate is pegged at $1.43, calling for 13.5% growth from the prior-year reported number. The same for revenues is pegged at $749.7 million, calling for 7.7% growth from the year-earlier reported number.The Zacks Consensus Estimate for fiscal 2020 earnings is pegged at $5.58 per share, suggesting a 14.1% rise from the year-ago quarter’s reported figure. The same for revenues stands at $2.99 billion, implying a 7.4% improvement from the year-earlier quarter’s reported number.Stocks Worth a LookA few other top-ranked stocks from the broader medical space are Haemonetics Corporation HAE, West Pharmaceutical Services WST and Omnicell OMCL. While Haemonetics sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.Haemonetics has a projected long-term earnings growth rate of 13.5%.Story continuesWest Pharmaceutical Services has an expected long-term earnings growth rate of 14%.Omnicell has a long-term earnings growth rate of 12.5%.Just Released: Zacks’ 7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.These 7 were selected because of their superior potential for immediate breakout.See these time-sensitive tickers now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Omnicell, Inc. (OMCL) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextUS gives Iran sanctions waiver for humanitarian tradeThe IndependentA Sliding Share Price Has Us Looking At Glory Sun Financial Group Limited's (HKG:1282) P/E RatioSimply Wall St.Do You Know What China Zhongwang Holdings Limited's (HKG:1333) P/E Ratio Means?Simply Wall St.Here’s how low stocks could go in a coronavirus ‘growth scare’MarketWatchPrince George & Princess Charlotte’s School Is Having A Coronavirus ScareRefinery29Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoAsian markets continue to slump, as Nikkei enters correction territoryMarketWatch'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video